Advertisement

Rheumatology International

, Volume 30, Issue 9, pp 1173–1176 | Cite as

The Hebrew version of the FibroFatigue scale: validation of a questionnaire for assessment of fibromyalgia and chronic fatigue syndrome

  • Jacob N. Ablin
  • Lisa Odes
  • Lily Neumann
  • Dan Buskila
Original Article

Abstract

The objective of this study is to validate a translated Hebrew version of the FibroFatigue Scale (FFS). The Hebrew version of the FFS was administered to 100 patients fulfilling ACR criteria for classification of FM together with the validated Hebrew version of the Fibromyalgia Impact Questionnaire (FIQ), the validated Hebrew version of the Short Form-36 (SF-36) and a Visual Analogue Scale (VAS) measurement of pain, anxiety, depression, morning stiffness and global well being. Test–retest reliability was assessed using Spearman correlations. Internal consistency was evaluated with Cronbach’s α of reliability. Construct validity of the FFS was evaluated by correlations among the FFS, the FIQ and the subscales of the SF-36. Mean duration of symptoms was 10.7 years, and mean age of participants was 53.5 years. Test–retest reliability was between 0.46 and 0.85 for the various FFS items. Internal consistency was 0.89 for the overall FFS. Significant correlations were obtained between the FFS items and the SF-36. These results support the reliability and validity of the data obtained with the Hebrew version of the FSS for detecting and measuring symptom severity in Hebrew speaking patients with FM.

Keywords

FIbromyalgia FibroFatigue scale Hebrew 

References

  1. 1.
    Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL et al (1990) The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33(2):160–172CrossRefPubMedGoogle Scholar
  2. 2.
    Clauw DJ, Crofford LJ (2003) Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol 17(4):685–701CrossRefPubMedGoogle Scholar
  3. 3.
    Dadabhoy D, Clauw DJ (2006) Therapy insight: fibromyalgia—a different type of pain needing a different type of treatment. Nat Clin Pract Rheumatol 2(7):364–372CrossRefPubMedGoogle Scholar
  4. 4.
    Arnold LM, Crofford LJ, Mease PJ, Burgess SM, Palmer SC, Abetz L et al (2008) Patient perspectives on the impact of fibromyalgia. Patient Educ Couns 73(1):114–120CrossRefPubMedGoogle Scholar
  5. 5.
    Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473–483CrossRefPubMedGoogle Scholar
  6. 6.
    Meenan RF, Gertman PM, Mason JH (1980) Measuring health status in arthritis. The arthritis impact measurement scales. Arthritis Rheum 23(2):146–152CrossRefPubMedGoogle Scholar
  7. 7.
    Buskila D, Neumann L (1996) Assessing functional disability and health status of women with fibromyalgia: validation of a Hebrew version of the Fibromyalgia Impact Questionnaire. J Rheumatol 23(5):903–906PubMedGoogle Scholar
  8. 8.
    Neumann L, Berzak A, Buskila D (2000) Measuring health status in Israeli patients with fibromyalgia syndrome and widespread pain and healthy individuals: utility of the short form 36-item health survey (SF-36). Semin Arthritis Rheum 29(6):400–408CrossRefPubMedGoogle Scholar
  9. 9.
    Neumann L, Dudnik Y, Bolotin A, Buskila D (1999) Evaluation of a Hebrew version of the revised and expanded Arthritis Impact Measurement Scales (AIMS2) in patients with fibromyalgia. J Rheumatol 26(8):1816–1821PubMedGoogle Scholar
  10. 10.
    Zachrisson O, Regland B, Jahreskog M, Kron M, Gottfries CG (2002) A rating scale for fibromyalgia and chronic fatigue syndrome (the FibroFatigue scale). J Psychosom Res 52(6):501–509CrossRefPubMedGoogle Scholar
  11. 11.
    Asberg M, Montgomery SA, Perris C, Schalling D, Sedvall G (1978) A comprehensive psychopathological rating scale. Acta Psychiatr Scand Suppl (271):5–27Google Scholar
  12. 12.
    Andersson M, Bagby JR, Dyrehag L, Gottfries C (1998) Effects of staphylococcus toxoid vaccine on pain and fatigue in patients with fibromyalgia/chronic fatigue syndrome. Eur J Pain 2(2):133–142CrossRefPubMedGoogle Scholar
  13. 13.
    Sarzi-Puttini P, Atzeni F, Turiel M, Furlan R, Vulpio L, Carrabba M et al (2004) The Italian version of the FibroFatigue scale, a reliable tool for the evaluation of fibromyalgia symptoms. J Psychosom Res 56(2):213–216CrossRefPubMedGoogle Scholar
  14. 14.
    Garcia-Campayo J, Pascual A, Alda M, Marzo J, Magallon R, Fortes S (2006) The Spanish version of the FibroFatigue scale: validation of a questionnaire for the observer’s assessment of fibromyalgia and chronic fatigue syndrome. Gen Hosp Psychiatry 28(2):154–160CrossRefPubMedGoogle Scholar
  15. 15.
    Lewin-Epstein N, Sagiv-Schifter T, Shabtai EL, Shmueli A (1998) Validation of the 36-item short-form Health Survey (Hebrew version) in the adult population of Israel. Med Care 36(9):1361–1370CrossRefPubMedGoogle Scholar
  16. 16.
    McCarty DJ Jr, Gatter RA, Steele AD (1968) A twenty-pound dolorimeter for quantification of articular tenderness. Arthritis Rheum 11(5):696–698CrossRefPubMedGoogle Scholar
  17. 17.
    Lundh HC, Wengstrom Y, Furst CJ (2008) Patterns of fatigue related to advanced disease and radiotherapy in patients with cancer-a comparative cross-sectional study of fatigue intensity and characteristics. Support Care Cancer 17:519–526CrossRefGoogle Scholar
  18. 18.
    Johansson S, Ytterberg C, Back B, Holmqvist LW, von Koch L (2008) The Swedish occupational fatigue inventory in people with multiple sclerosis. J Rehabil Med 40(9):737–743PubMedGoogle Scholar
  19. 19.
    Iaboni A, Ibanez D, Gladman DD, Urowitz MB, Moldofsky H (2006) Fatigue in systemic lupus erythematosus: contributions of disordered sleep, sleepiness, and depression. J Rheumatol 33(12):2453–2457PubMedGoogle Scholar
  20. 20.
    Riemsma RP, Rasker JJ, Taal E, Griep EN, Wouters JM, Wiegman O (1998) Fatigue in rheumatoid arthritis: the role of self-efficacy and problematic social support. Br J Rheumatol 37(10):1042–1046CrossRefPubMedGoogle Scholar
  21. 21.
    Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A (1994) The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 121(12):953–959PubMedGoogle Scholar
  22. 22.
    Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP Jr, Martin SA et al (2008) A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 35(3):502–514PubMedGoogle Scholar
  23. 23.
    Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ et al (2008) Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 136:432–444CrossRefPubMedGoogle Scholar
  24. 24.
    Gendreau RM, Thorn MD, Gendreau JF, Kranzler JD, Riberio S, Gracely RH et al (2005) The efficacy of Milnacipran in Fibromyalgia. J Rheumatol 32:1975–1985PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Jacob N. Ablin
    • 1
  • Lisa Odes
    • 2
  • Lily Neumann
    • 3
  • Dan Buskila
    • 4
  1. 1.Institute of Rheumatology and Internal Medicine 6Tel Aviv Sourasky Medical CenterTel AvivIsrael
  2. 2.Department of MedicineSoroka Medical CenterBeershebaIsrael
  3. 3.Epidemiology Department, Faculty of Health SciencesBen-Gurion University of the NegevBeershebaIsrael
  4. 4.Division of Internal Medicine, Department of Medicine H, Soroka Medical CenterBen Gurion UniversityBeershebaIsrael

Personalised recommendations